Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

v3.22.2
Summary of Significant Accounting Policies - Additional Information (Details)
 1 Months Ended 12 Months Ended
Sep. 17, 2021
shares
Aug. 11, 2021
$ / shares
shares
Jan. 06, 2021
USD ($)
$ / shares
shares
Jan. 03, 2020
shares
Oct. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
item
shares
Dec. 31, 2020
USD ($)
item
shares
Goodwill           $ 0 $ 3,631,212
Impairment loss on goodwill           4,037,811 0
In-process R&D           10,599,000 9,536,000
Accrued clinical expenses           168,785 203,646
Deferred Tax Liabilities, Net           802,131 728,926
Unrecognized uncertain income tax           $ 0 $ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | shares           41,216 77,262
Other assets or liabilities that are subject to fair value methodology and estimation           $ 0 $ 0
Number of vendors with whom the company has entered into related party transactions | item           1 2
Number of consultants with whom the company has entered into related party transactions | item           6 7
Shares issued | shares 10,911 4,668,844 1,531,101 500,000      
Warrants to purchase common stock | shares   233,442          
Purchase price | $ / shares   $ 2.3025          
Net proceeds from the private placement     $ 8,000,000.0        
Related party transactions payments related to services provided             $ 502,000
Decrease in contingent consideration           $ (475,956) (1,230,170)
Common Stock | Private Placement              
Shares issued | shares     1,531,101        
Warrants to purchase common stock | shares     1,531,101        
Purchase price | $ / shares     $ 5.225        
Net proceeds from the private placement           $ 8,000,000.0  
Maximum              
Estimated useful life (in years)           5 years  
Minimum              
Estimated useful life (in years)           2 years  
Jade acquisition              
Fair value of contingent consideration           $ 580,000 480,000
Decrease in contingent consideration           100,000  
Panoptes acquisition              
Money Market Funds Fair Value             $ 2,067,000.000
Fair value of contingent consideration           1,593,000  
Decrease in contingent consideration           474,000  
Bayon acquisition              
Impairment loss on goodwill         $ 407,000    
In-process R&D         302,000    
Decrease in contingent consideration         $ 381,000    
Contingent consideration           $ 876,000